Novartis mRNA Bet Puts Pipeline Governance on Trial
Novartis is paying $575 million upfront for Abogen’s mRNA platform while keeping most of a $7.8 billion headline contingent. The real test is disciplined…
Read the storyTag: Biotechnology
Sanofi Regeneron Deal Turns an $8 Billion Headline Into an Immunology Option
Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestones. The structure turns litigation into a staged immunology option—and makes…
Read the story